At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Subclinical Cardiovascular Disease in Psoriatic Disease
In Brief
A Phase 4 clinical trial evaluating Aspirin and/or Atorvastatin for Cardiovascular Diseases and 3 related conditions. Completed, enrolled 63 participants across 1 site.
Detailed Summary
This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk. The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic disease and measures of vascular function. 2) Evaluate the association between moderate to severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional medications used in cardiovascular disease (CVD) prevention such as aspirin and statins affect vascular function and thrombotic risk in those with moderate to severe psoriatic disease.
Study Details
Timeline
Interventions
This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.